Risk factors of acute tacrolimus nephrotoxicity in renal allografts.
Shimizu
T
T
Department of Urology, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.
Tanabe
K
K
Tokumoto
T
T
Ishikawa
N
N
Shimmura
H
H
Oshima
T
T
Toma
H
H
Yamaguchi
Y
Y
D000017:ABO Blood-Group System; D000328:Adult; D000367:Age Factors; D001379:Azathioprine / Q000627:therapeutic use; D001787:Blood Group Incompatibility; D003404:Creatinine / Q000097:blood; D003920:Diabetes Mellitus / Q000453:epidemiology; D004359:Drug Therapy, Combination; D005260:Female; D006684:HLA-DR Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology* / Q000502:physiology; D019520:Living Donors; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D012307:Risk Factors; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use; D014019:Tissue Donors; D014184:Transplantation, Homologous
D000017:ABO Blood-Group System; D006684:HLA-DR Antigens; D007166:Immunosuppressive Agents; D003404:Creatinine; D001379:Azathioprine; D016559:Tacrolimus; D008775:Methylprednisolone